Literature DB >> 27210019

Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Rachel Beckerman, Kathryn Yoh1, Melissa Mattia-Sansobrino, Andrew Zupnick, Oleg Laptenko1, Orit Karni-Schmidt1, Jinwoo Ahn2, In-Ja Byeon2, Susan Keezer3, Carol Prives1.   

Abstract

Functional in a tetrameric state, the protein product of the p53 tumor suppressor gene confers its tumor-suppressive activity by transactivating genes which promote cell-cycle arrest, senescence, or programmed cell death. How p53 distinguishes between these divergent outcomes is still a matter of considerable interest. Here we discuss the impact of 2 mutations in the tetramerization domain that confer unique properties onto p53. By changing lysines 351 and 357 to arginine, thereby blocking all post-translational modifications of these residues, DNA binding and transcriptional regulation by p53 remain virtually unchanged. On the other hand, by changing these lysines to glutamine (2KQ-p53), thereby neutralizing their positive charge and potentially mimicking acetylation, p53 is impaired in the induction of cell cycle arrest and yet can still effectively induce cell death. Surprisingly, when 2KQ-p53 is expressed at high levels in H1299 cells, it can bind to and transactivate numerous p53 target genes including p21, but not others such as miR-34a and cyclin G1 to the same extent as wild-type p53. Our findings show that strong induction of p21 is not sufficient to block H1299 cells in G1, and imply that modification of one or both of the lysines within the tetramerization domain may serve as a mechanism to shunt p53 from inducing cell cycle arrest.

Entities:  

Keywords:  acetylation; apoptosis; cell cycle; p21; tumor suppressor p53

Mesh:

Substances:

Year:  2016        PMID: 27210019      PMCID: PMC4934057          DOI: 10.1080/15384101.2016.1170270

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  86 in total

1.  Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo.

Authors:  M D Kaeser; R D Iggo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

Review 2.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

3.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 4.  Transcriptional regulation by p53: one protein, many possibilities.

Authors:  O Laptenko; C Prives
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

5.  Mechanistic insights into maintenance of high p53 acetylation by PTEN.

Authors:  Andrew G Li; Landon G Piluso; Xin Cai; Gang Wei; William R Sellers; Xuan Liu
Journal:  Mol Cell       Date:  2006-08       Impact factor: 17.970

6.  Identification of new p53 acetylation sites in COS-1 cells.

Authors:  Anita Joubel; Robert J Chalkley; Katalin F Medzihradszky; Hubert Hondermarck; Alma L Burlingame
Journal:  Mol Cell Proteomics       Date:  2009-01-19       Impact factor: 5.911

Review 7.  p53: traffic cop at the crossroads of DNA repair and recombination.

Authors:  Sagar Sengupta; Curtis C Harris
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

8.  Refined solution structure of the oligomerization domain of the tumour suppressor p53.

Authors:  G M Clore; J Ernst; R Clubb; J G Omichinski; W M Kennedy; K Sakaguchi; E Appella; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1995-04

9.  Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Authors:  S Rowan; R L Ludwig; Y Haupt; S Bates; X Lu; M Oren; K H Vousden
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

10.  Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain.

Authors:  Michela Muscolini; Elisa Montagni; Silvana Caristi; Takao Nomura; Rui Kamada; Silvia Di Agostino; Marco Corazzari; Mauro Piacentini; Giovanni Blandino; Antonio Costanzo; Kazuyasu Sakaguchi; Loretta Tuosto
Journal:  Cell Cycle       Date:  2009-10-24       Impact factor: 4.534

View more
  7 in total

1.  A new function for p53 tetramerization domain in cell fate control.

Authors:  Jin Zhang; Christopher Lucchesi; Xinbin Chen
Journal:  Cell Cycle       Date:  2016-06-29       Impact factor: 4.534

2.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

3.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

4.  Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.

Authors:  Viola Ellison; George K Annor; Clara Freedman; Gu Xiao; Devon Lundine; Elzbieta Freulich; Carol Prives; Jill Bargonetti
Journal:  Oncotarget       Date:  2021-06-08

5.  p53 Frameshift Mutations Couple Loss-of-Function with Unique Neomorphic Activities.

Authors:  David R Tong; Wen Zhou; Chen Katz; Kausik Regunath; Divya Venkatesh; Chinyere Ihuegbu; James J Manfredi; Oleg Laptenko; Carol Prives
Journal:  Mol Cancer Res       Date:  2021-05-27       Impact factor: 5.852

Review 6.  The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases.

Authors:  Thineskrishna Anbarasan; Jean-Christophe Bourdon
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

Review 7.  p53 tetramerization: at the center of the dominant-negative effect of mutant p53.

Authors:  Jovanka Gencel-Augusto; Guillermina Lozano
Journal:  Genes Dev       Date:  2020-09-01       Impact factor: 11.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.